• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    11/14/24 6:46:41 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANNX alert in real time by email
    SC 13G/A 1 annx13ga2.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)

    Annexon, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    03589W102

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 03589W102

     

     

    1.Names of Reporting Persons.

    Logos Global Management LP

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 2,900,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 2,900,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,900,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.7%

     

    12.Type of Reporting Person (See Instructions) IA, PN

     2 
    CUSIP No. 03589W102

     

     

    1.Names of Reporting Persons.

    Logos Global Management GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 2,900,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 2,900,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,900,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.7%

     

    12.Type of Reporting Person (See Instructions) HC, OO

     

     3 
    CUSIP No. 03589W102

     

     

    1.Names of Reporting Persons.

    Arsani William

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 2,900,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 2,900,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,900,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.7%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 03589W102

     

     

    1.Names of Reporting Persons.

    Logos Global Master Fund LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ___X__

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 2,900,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 2,900,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,900,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.7%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     5 
    CUSIP No. 03589W102

     

     

    1.Names of Reporting Persons.

    Logos GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 2,900,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 2,900,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,900,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.7%

     

    12.Type of Reporting Person (See Instructions) OO

     

     6 
    CUSIP No. 03589W102

     

     

    Item1.
    (a)Name of Issuer

    Annexon, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, CA 94005

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    Logos Global Master Fund LP (“Global Fund”), Logos Global Management LP (“Logos Global”), Logos GP LLC (“Logos GP”), Logos Global Management GP LLC (“Logos Global GP”), and Arsani William (collectively, the “Filers”).

     

    Logos Global is the investment adviser to investment funds, including Global Fund. Logos Global GP is the general partner of Logos Global. Dr. William is a control person of Logos Global and Logos Global GP.

     

    The Filers are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. In addition, filing this Schedule 13G on behalf of Global Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    One Letterman Drive, Building C, Suite C3-350, San Francisco, California 94129

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Common Stock, $0.001 par value (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 03589W102.
     7 
    CUSIP No. 03589W102

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to Logos Global.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Logos Global GP and Dr. William.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The percentages reported in this Schedule 13G are based on 105,653,962 as of August 8, 2024, as reported in the Form 10-Q filed by the Issuer on August 12, 2024.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    The funds managed by Logos Global, including Global Fund, hold the Stock for the benefit of their investors and have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of Logos Global, Logos Global GP and Dr. William:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Global Fund and Logos GP:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     8 
    CUSIP No. 03589W102

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     
    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

     9 
    CUSIP No. 03589W102

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Logos Global Management LP, a Delaware limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Act, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: November 14, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     
    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

     

    Get the next $ANNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANNX

    DatePrice TargetRatingAnalyst
    3/1/2024$11.00Neutral → Overweight
    JP Morgan
    12/21/2023$4.00 → $6.00Neutral → Buy
    BofA Securities
    10/30/2023$11.00Overweight
    Wells Fargo
    5/26/2023$8.00 → $3.00Buy → Neutral
    BofA Securities
    5/25/2023$19.00 → $9.00Overweight → Neutral
    JP Morgan
    9/16/2022$12.00Buy
    Jefferies
    9/9/2022$15.00Buy
    BTIG Research
    11/30/2021$40.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ANNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

      First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current Standards of Care in Matched Patient Populations New Analyses of Phase 3 Trial Highlight Tanruprubart's Early and Durable Treatment Effect and Improvement in Quality of Life in Patients with GBS BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye

      5/9/25 5:00:00 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

      Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial Enrolling Globally BRISBANE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on the neuroprotective effect of ANX007, including consistent benefits of C1q inhibition against inflammation and neuronal damage across diseases. The presentati

      5/7/25 8:00:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on April 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). The new non-executive employee received an option to purchase 105,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per sh

      4/16/25 4:05:18 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Annexon Inc.

      SC 13G/A - Annexon, Inc. (0001528115) (Subject)

      11/14/24 7:21:59 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Annexon Inc.

      SC 13G/A - Annexon, Inc. (0001528115) (Subject)

      11/14/24 6:46:41 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Annexon Inc.

      SC 13G/A - Annexon, Inc. (0001528115) (Subject)

      11/14/24 5:30:27 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Annexon upgraded by JP Morgan with a new price target

      JP Morgan upgraded Annexon from Neutral to Overweight and set a new price target of $11.00

      3/1/24 7:27:25 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon upgraded by BofA Securities with a new price target

      BofA Securities upgraded Annexon from Neutral to Buy and set a new price target of $6.00 from $4.00 previously

      12/21/23 6:41:39 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Annexon with a new price target

      Wells Fargo initiated coverage of Annexon with a rating of Overweight and set a new price target of $11.00

      10/30/23 7:48:24 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & CHIEF SCIENTIFIC OFFICER Artis Dean Richard was granted 44,963 shares, increasing direct ownership by 54% to 128,777 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      3/3/25 4:56:38 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF MEDICAL OFFICER Dananberg Jamie was granted 44,963 shares, increasing direct ownership by 134% to 78,442 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      3/3/25 4:55:35 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & CHIEF FINANCIAL OFFICER Lew Jennifer was granted 44,963 shares, increasing direct ownership by 58% to 122,733 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      3/3/25 4:52:12 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Annexon Inc.

      SCHEDULE 13G/A - Annexon, Inc. (0001528115) (Subject)

      4/30/25 10:54:11 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Annexon Inc.

      DEFA14A - Annexon, Inc. (0001528115) (Filer)

      4/23/25 4:03:09 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Annexon Inc.

      DEF 14A - Annexon, Inc. (0001528115) (Filer)

      4/23/25 4:01:32 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Expands Board of Directors with Appointment of Commercial Executive William "BJ" Jones

      BRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of  William "BJ" Jones to its board of directors. Mr. Jones brings 30 years of U.S. and global commercial and launch experience in the biotechnology industry. "We are thrilled to add BJ to our board of directors at this transformative time for Annexon," said Douglas Love, president and chief executive officer of Annexon. "His deep commercial expertise and proven experience

      1/10/25 8:00:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio

      BRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain, and eye, today announced the strengthening of its senior leadership team with the appointment of Shikhar Agarwal, M.B.A. as senior vice president, head of commercial, Sunil B. Mehta, Pharm.D as senior vice president of medical affairs and Myoung Kim, PHD, M.A., M.B.A. as vice president of health economics and outcomes research. "We are excited to welcome Shikhar, Sunil and Myoung to the Annexon family as we prepare for commercial development of our flagship programs in Guillain-Barré Syndrome (

      9/3/24 8:00:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Financials

    Live finance-specific insights

    See more
    • Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

      Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the

      12/16/24 7:30:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

      Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Comparability Data Expected in First Half 2025 Conference call and webcast today at 8:30 a.m. ET BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage platform of novel ther

      6/4/24 7:00:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

      BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data. Conference Call and Webcast InformationThe live webcast and replay may be accessed by visiting Annexon's website here. The dial-in number is 1-877-407-0784 (U.S./Canada) or 1-201-689-8560 (international). The conference ID for all callers is 13747058. The Call me™ link may be accessed here. Participants can use guest

      6/3/24 4:30:00 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Carson William H. bought $17,056 worth of shares (3,200 units at $5.33), increasing direct ownership by 14% to 25,600 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      12/4/24 6:12:46 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Carson William H. bought $19,104 worth of shares (3,200 units at $5.97), increasing direct ownership by 17% to 22,400 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      10/2/24 4:15:17 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Carson William H. bought $17,536 worth of shares (3,200 units at $5.48), increasing direct ownership by 20% to 19,200 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      9/4/24 4:34:40 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care